Xbrane Biopharma AB Stock

Equities

XBRANE

SE0007789409

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 11:29:50 2024-04-23 am EDT 5-day change 1st Jan Change
0.2155 SEK -8.30% Intraday chart for Xbrane Biopharma AB -36.71% -97.84%
Sales 2024 * 372M 34.43M Sales 2025 * 785M 72.62M Capitalization 330M 30.51M
Net income 2024 * -101M -9.35M Net income 2025 * 211M 19.53M EV / Sales 2024 * 0.51 x
Net cash position 2024 * 138M 12.81M Net cash position 2025 * 21.29M 1.97M EV / Sales 2025 * 0.39 x
P/E ratio 2024 *
-2.16 x
P/E ratio 2025 *
0.04 x
Employees 93
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.48%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Xbrane Biopharma AB

1 day-8.30%
1 week-36.71%
Current month-28.52%
1 month-56.55%
3 months-88.40%
6 months-98.90%
Current year-97.84%
More quotes
1 week
0.21
Extreme 0.21
0.37
1 month
0.21
Extreme 0.21
0.43
Current year
0.21
Extreme 0.21
10.84
1 year
0.21
Extreme 0.21
98.00
3 years
0.21
Extreme 0.21
180.40
5 years
0.21
Extreme 0.21
180.40
10 years
0.21
Extreme 0.21
180.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 14-12-31
Director of Finance/CFO 63 21-01-10
Chief Tech/Sci/R&D Officer 42 17-10-08
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Director/Board Member 70 14-12-31
Director/Board Member 53 19-12-31
More insiders
Date Price Change Volume
24-04-23 0.2155 -8.30% 64,018,490
24-04-22 0.235 -33.24% 198,129,300
24-04-19 0.352 -3.30% 20,968,650
24-04-18 0.364 +6.59% 24,708,150
24-04-17 0.3415 +0.29% 19,843,070

Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:29 am EDT

More quotes
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. XBRANE Stock